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The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several
neurological diseases including multiple sclerosis (MS). Quinolinic acid levels are elevated in experimental
autoimmune encephalomyelitis rodents, the widely used animal model of MS. Our group has also found
pathophysiological concentrations of quinolinic acid in MS patients. This led us to investigate the effect of quinolinic
acid on oligodendrocytes; the main cell type targeted by the autoimmune response in MS. We have examined the
kynurenine pathway (KP) profile of two oligodendrocyte cell lines and show that these cells have a limited threshold to
catabolize exogenous quinolinic acid. We further propose and demonstrate two strategies to limit quinolinic acid
gliotoxicity: 1) by neutralizing quinolinic acid’s effects with anti-quinolinic acid monoclonal antibodies and 2) directly
inhibiting quinolinic acid production from activated monocytic cells using specific KP enzyme inhibitors. The outcome
of this study provides a new insight into therapeutic strategies for limiting quinolinic acid-induced neurodegeneration,
especially in neurological disorders that target oligodendrocytes, such as MS.
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Quinolinic acid (QUIN) is a downstream metabolite pro-
duced through the kynurenine pathway (KP) of trypto-
phan metabolism [1,2]. In physiological conditions, QUIN
is present in nanomolar concentrations and used as
substrate by cells to synthesize the essential co-factor
nicotinamide adenine dinucleotide (NAD+). However,
during neuroinflammation, the KP can be chronically or
acutely activated through the induction of one of its initial
enzymes, indoleamine 2,3-dioxygenase (IDO-1). QUIN is
then produced in excess and can kill brain cells including
neurons, astrocytes and oligodendrocytes by at least six
different mechanisms [2,3]. QUIN has been implicated in
several neurological diseases, including multiple sclerosis
(MS) [4,5]. The involvement of the KP in neurological dis-
eases is complex, as it revolves around the metabolic* Correspondence: gilles.guillemin@mq.edu.au
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unless otherwise stated.balance between excessive production of neurotoxic me-
tabolites, such as QUIN, and neuroprotective compounds,
such as kynurenic acid (KYNA) [6,7].
At the cellular level, QUIN is cytotoxic for most of the
brain cell types in vitro at micromolar concentrations.
Cammer [8,9] showed that exposure to 1 mM of QUIN
induces cell death in rat oligodendrocytes [8,9]. Similar
toxic effects are also observed in primary human astro-
cytes and neurons at pathophysiological concentrations
of 150 nM [10], and more recently in motor neurons at
concentrations of 100 nM [11]. Furthermore, this effect
can be abolished by using antagonists of the N-methyl-
D-aspartate (NMDA) receptor - such as memantine,
MK801 and AP-V - implying excitotoxicity as the main
mechanism inducing cell death [10,11]. Current evidence
suggests only monocytic lineage cells have the ability to
produce QUIN [12,13]. Brain cell types, including neu-
rons, astrocytes, pericytes and endothelial cells are likely
to uptake QUIN and catabolize it [14-17].
The function of the KP in oligodendrocytes remains to
be investigated, although an earlier study demonstrated
that IDO-1 and tryptophan 2,3-dioxygenase (TDO-2)tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[5]. This potentially has strong implications for MS
pathology. The lack of these two KP regulatory enzymes
in oligodendrocytes is associated with a higher cell sus-
ceptibility to allogenic T-cell challenge, since IDO-1
plays a crucial role in immune regulation - particularly
in suppressing T cell proliferation [18]. The KP profile
has been shown to be altered in both MS patients and in
experimental autoimmune encephalitis (EAE) mouse
models [19-21]. Rejdak et al. [19] reported that the con-
centration of the neuroprotective KYNA in the cerebro-
spinal fluid (CSF) of MS patients is decreased during the
remission stage. This indicates that the KP stays inclined
towards neurodegeneration long after inflammation. We
hypothesise that in MS the sustained activation of the
KP in the CNS leads to an unbalanced production
favoring neurotoxic over neuroprotective intermediates.
This study investigates the profile of the KP in oligo-
dendrocytes and characterizes to what extent KP metab-
olism changes during immune challenge. We have also
identified novel approaches to protect oligodendrocytes
against pathophysiological concentrations of QUIN. The
outcomes of this study could have significant implica-
tions for potential therapeutic strategies in MS and other
neurodegenerative diseases that involve KP dysregulation
with overproduction of QUIN.
Material and methods
Cell cultures
Mouse oligodendroglial cell lines (N19 and N20.1) were
kindly provided by Dr. A T Campagnoni (University of
California, Los Angeles, CA, USA). These cells were con-
ditionally immortalized oligodendrocytes isolated from
normal and shiverer primary mouse brain cultures through
the use of the retroviral vector pZIPSVtsA58 encoding im-
mortalizing thermolabile simian virus 40 large T antigen
that allows for clonal selection by conferring neomycin
(G418) resistance [22]. N19 and N20.1 were chosen for
their differences in developmental maturity along the
oligodendrocyte lineage. N19 represent oligodendroglial
cells with a relatively immature or precursor phenotype,
whereas N20.1 represent a more mature phenotype.
Oligodendroglial cells were cultured in accordance with
the previously published method [22,23]. Briefly, cells were
seeded and grown in flask coated with poly-L-lysine
to confluence at 34°C, the permissive temperature, in
DMEM/F12; Invitrogen, Melbourne, Australia) supple-
mented with 10% FBS, 100 μg/ml of gentamicin, 100 μg/
ml of G418 (Invitrogen, Melbourne, Australia) and then
shifted to 39°C, the non-permissive temperature that leads
to 'differentiated' state for 72 hours. In all the experiments,
during incubation at 39°C, the medium was replaced by
fresh DMEM/F12 with 1% FBS and maintained for 7 days
before treatments.The BV2 cell line was kindly donated by Dr. T Kuffner
(St Vincent’s Center for Applied Medical Research,
Sydney, Australia). The culture method for the BV2
murine microglial cells was adapted from Laurenzi and
Arcuri et al. [24]. Briefly, BV2 cells were maintained in
DMEM supplemented with 10% FBS, Glutamax and
antibiotic-anti-mycotic solution. The mouse macrophage
cell line RAW264.7 was kindly donated by Prof. Nicholas
Hunt (University of Sydney). The RAW264.7 cells were
cultured based on the method adapted from Watts and
Hunt et al. [25].
The study conditions were: (1) unstimulated; (2) IFN-γ
stimulated oligodendroglial cell lines (N19 and N20.1);
and (3) IFN-γ-treated macrophage cell line, RAW 264.7
as a positive control, since macrophages are known to ex-
press all the KP enzymes [14]. The study design included
3 time points: 24, 48 and 72 hours based on previous simi-
lar studies showing peak mRNA expression of KP enzymes
at 24 hours, whilst production of KP metabolites peaks at
72 hours post-treatment (data not shown) [15,16].
Characterization of KP enzymes by quantitative RT-PCR
The qRT-PCR protocol used has been previously de-
scribed [26]. The primer sequences used to detect mouse
KP enzymes are summarized in Table 1. Primers were
obtained from several sources: designed by Dr. Fabrice
Magnino (PCR/qPCR specialist Integrated Sciences Pty
Limited), a gift from collaborating researchers, Primer
Bank (http://pga.mgh.harvard.edu/primerbank/) or de-
signed by using Primer BLAST (web-based NCBI primer
designing tool: http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) or Primer3 designing program (http://primer3.
sourceforge.net/). RPL13 was used as the endogenous ref-
erence gene. Data are presented as fold differences in gene
expression normalized to RPL13 and relative to the un-
treated control. Differences in the relative expression of
each gene were analyzed using Student’s t-test. Statistical
significance was accepted at P < 0.05. Reported values are
mean ± SE of triplicate samples.
Immunocytochemistry
To characterize the KP in both N19 and N20.1 cell lines,
cells were cultured onto slide flasks (Nunc, Rochester,
NY, USA) at 34°C and when 70% confluence was reached
they were incubated at 39°C for 72 hours. After 3 days, the
cells were either left untreated or treated with 100 IU/ml
of IFN-γ for 24 hours. The cells were then stained for
indoleamine 2,3-dioxygenase 1 (IDO-1) (Biolegend, San
Diego, CA, USA), tryptophan 2,3-dioxygenase (TDO-2;
generous gift from Dr. CL Miller John Hopkins University,
Baltimore, MD, USA), kynurenine 3-monooxygenase
(Abcam, Cambridge, UK), QUIN (Millipore, Bedford, MA,
USA), picolinic acid (PIC; Abcam, Cambridge, UK), 2',3'-
cyclic nucleotide 3'-phosphodiesterase (CNP; Millipore,
Table 1 Primer sequences for qRT-PCR
Gene ID Accession number Primer sequence
Indoleamine 2,3-dioxygenase IDO1 NM_008324 FWD TGT GAA TGG TCT GGT CTC
REV CTG TGC CCT GAT AGA AGT
Tryptophan 2,3-dioxygenase TDO2 BC018390.1 FWD TGC TCA AGG TGA TAG CTC GGA
REV AGG AGC TTG AAG ATG ACC ACC A
Kynurenine aminotransferase 1 KAT1 NM_172404 FWD GCT TTT CAG CAG GCT ACC AC
REV CCA CTG TCA CCA GCA CAT TC
Kynurenine aminotransferase 2 KAT2 AF072376 FWD GAA CTT CTG TCC TGG CTA A
REV CTT GAT TGG GTG GGT AGT
Kynureninase KYNU NM_027552 FWD GAG CAG AGG AGC GTG GCT GC
REV GAA CAG GGG CCA CGC GGA TG
3-hydroxyanthranilate 3,4-dioxygenase 3HAO NM_025325 FWD TTC AGC CTC ATT GCA TCT
REV GAC AGT GTA GGG CTA TGG
Kynurenine 3-monoxygenase KMO NM_133809.1 FWD GGT CGC CTT CAC CAG AAT AA
REV ATC CAG GCA GGT CTT CTC AA
Aminocarboxymuconate semialdehyde decarboxylase ACMSD NM_001033041 FWD GAA TAA ATG CTG ACC CAA CA
REV TTC ATC CAT CCT TCC AGA C
Quinolinate phosphoribosyl transferase QPRT NM_133686.1 FWD CTG CTC CAA GTC ACC ATG
REV CAG AAC CCC AGG AGA TTT
Ribosomal protein L13 RPL13 NM_016738.5 FWD GAG GTC GGG TGG AAG TAC CA
REV TGC ATC TTG GCC TTT TCC TT
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Abcam, Cambridge, UK) according to previously de-
scribed protocol [15,16]. The antibodies are summarized
in Tables 2 and 3. Untreated cells were stained and used
as experimental control for comparison. Experiments were
performed in triplicate and independently validated with
three biological replicates.
Quantification of KP metabolites
Tryptophan, kynurenine, and kynurenic acid were mea-
sured using high performance liquid chromatography
(HPLC) while picolinic acid and QUIN were concurrently
measured using gas chromatography/mass spectrometryTable 2 Summary of primary antibodies
Antibody Diluti
Myelin basic protein (MBP) 1:100
2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) 1:50
Vimentin (VIM) 1:100
Glial fibrillary acidic protein (GFAP) 1:750
Indoleamine 2,3-dioxygenase 1 (IDO1) 1:100
Tryptophan 2,3-dioxygenase (TDO) 1:100
Kynurenine 3-monooxygenase (KMO) 1:100
Quinolinic acid (QUIN) 1:100
Picolinic acid (PIC) 1:100(GC/MS) as previously described [11]. Results of tryptophan
and kynurenine were presented as kynurenine/tryptophan
(K/T) ratio, a reliable measure of KP activation. Produc-
tion or degradation of the KP metabolites was calculated
by subtracting the values of post- and pre-treatment con-
centrations of the KP metabolites present in the culture
medium.
QUIN toxicity and cell protection assays
QUIN toxicity and cell protection assays against QUIN
were determined by calculating the percentage of cell sur-
vival rate in comparison to untreated controls using Cyto-
Tox 96® Non-Radioactive cytotoxicity assay kit (Promega,on Isotype Company
Monoclonal - IgG Abcam
Monoclonal - IgG Millipore
Monoclonal - IgG Millipore
Monoclonal - IgG Dako
Monoclonal - IgG Biolegend
Polyclonal [27]
Polyclonal Abcam
Monoclonal - IgG Millipore
Monoclonal - IgG Abcam
Table 3 Summary of secondary antibodies
Antigen Dilution Isotype Company
Alexa Fluor 488 (green) 1:250 Goat anti-mouse IgG Invitrogen
Alexa Fluor 488 (green) 1:250 Goat anti-rabbit IgG Invitrogen
Alexa Fluor 594 (red) 1:250 Goat anti-mouse IgG Invitrogen
Alexa Fluor 594 (red) 1:250 Goat anti-rabbit IgG Invitrogen
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parts:
A)QUIN toxicity on oligodendrocytes: to assess the
QUIN toxicity, oligodendroglial cells were
challenged with varying concentrations of exogenous
QUIN up to 4 μM over 3 time points (24, 48 and
72 hours) and QUIN toxicity assessed. These data
were used to determine the LD50 of QUIN toxicity
and select the appropriate treatment period in
subsequent QUIN antagonism experiments (Parts C
and D).
B) QUIN uptake assays: to further demonstrate the
uptake of QUIN in oligodendrocytes, cells were
grown in slide flasks (Nunc, Rochester, NY, USA)
and treated with LD50 dose described in Part A for
0, 30, 60 and 90 minutes using protocol adapted
from [28]. QUIN uptake was then visualized using
immunocytochemistry as described previously [11,28].
C) Neutralization of QUIN with an anti-QUIN
monoclonal antibody (mAb): to fully assess the
potential of neutralizing QUIN toxicity with an
anti-QUIN mAb, we subjected the oligodendroglial
cells to 2 different conditions: 1. treated directly on
oligodendroglial cell lines with exogenous QUIN
followed by varying concentrations of QUIN-mAb
with the following three conditions: (a) pre-treatment
with QUIN (QUIN-PRE) for 72 hours at LD50
concentration followed by the QUIN-mAb for
30 minutes; (b) pre-treatment with anti-QUIN mAb
for 30 minutes followed by QUIN (QUIN-POST) at
LD50 concentration for 72 hours and; (c) concomitant
treatment with QUIN and the anti-QUIN mAb
(QUIN +QUIN mAb) together for 72 hours. 2.
treated with IFN-γ-treated BV2 cells supernatant
(endogenous QUIN) on oligodendroglial cell lines
followed by varying concentrations of QUIN mAb.
Cell death was then determined by measuring lactate
dehydrogenase (LDH) in the culture supernatant.
D) Inhibition of QUIN production with IDO-1
inhibitors: to imitate QUIN production during
inflammation and immune activation, BV2 cells were
stimulated with IFN-γ for 24 hours to induce
pathophysiological concentrations of QUIN
production. Oligodendrocyte cell line cultures were
then exposed to this QUIN-containing BV2 culturesupernatant for 72 hours and assessed for QUIN
toxicity. Further, the QUIN-producing BV2 cells
were challenged with 4 specific IDO-1 inhibitors
namely, 1-methyl-D-tryptophan (D-1MT),
1-methyl-L-tryptophan (L-1MT), 1-methyl-D-
tryptophan (DL-1MT) and berberine (5,6-dihydro-
9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]
quinolizinium) for 30 minutes to block QUIN
production as a potential therapeutic strategy to
alleviate QUIN toxicity during neuroinflammation.
Statistical analysis
Results are expressed as mean ± SE. Differences between
treatment groups for RT-PCR, GC/MS and HPLC data
were analyzed using Student’s t-test. QUIN toxicity study
results were compared using linear and multiple re-
gression analysis. QUIN mAb treatment results were
analyzed using the Mann-Whitney test. In all experi-
ments a P-value < 0.05 was considered significant.
Results
KP profiling in oligodendroglial cell lines N19 and N20.1
We found that both mice oligodendrocytic cell lines
N19 and N20.1 have a functional KP. This is evident at
gene, protein and metabolite level in N19 (Figure 1a-d)
and N20.1 (Figure 1e-h). However, the profile of KP ex-
pression in N19 was significantly different from N20.1
(see Additional files 1 and 2). By comparing the levels of
mRNA expression for the KP enzymes, after normaliza-
tion with the endogenous reference gene RPL13, we
showed that N20.1 had a much higher level of expression
for TDO-2 (P < 0.001) than N19 (Figure 1a and e). This re-
sult was validated at protein level using immunocyto-
chemistry (Figure 1b and f). Both cell lines showed
increased mRNA expression for TDO2 when treated with
pro-inflammatory cytokine IFN-γ. In N20.1 cells most KP
enzymes were up-regulated by IFN-γ, except ACMSD (see
Additional file 1). As expected, treatment with IFN-γ led
to an increased KP activation shown by the increased K/T
ratio in both cell lines (Figure 1c and g). Interestingly this
increase was due to an up-regulation of TDO-2 rather
than IDO-1 gene expression in N19.
KAT-1 and KAT-2 expression in both N19 and N20.1
suggests that oligodendrocytes are capable of producing
the neuroprotective metabolite KYNA. Indeed, KYNA
was detected in the culture media of both oligodendro-
cytic cell lines following background subtraction (serum
supplemented media). Although there was a significant
increase in KAT-1 and KAT-2 gene expression in N20.1
cells (see Additional file 1) following IFN-γ treatment,
there was no significant difference in the levels of KYNA
produced (Figure 1d and h). ACMSD activity was low in
both cell lines (see Additional file 1) and no production
of PIC was detected in culture media of the cell lines
Figure 1 Characterization of the kynurenine pathway (KP) in N19 (a-e) and N20.1 (e-h) oligodendroglial cell lines. Levels of TDO-2
transcripts in (a) N19 and (e) N20.1 cells in differentiated state, with or without IFN-γ treatment. N19 cells (b) and N20.1 cells (f) showed positive
TDO-2 cytoplasmic staining after 24 hours IFN-γ treatment. KP metabolic profile of oligodendroglial cell lines K/T ratio in N19 (c) and N20.1
(g) and kynurenic acid (KYNA), picolinic acid (PIC) and quinolinic acid (QUIN) profiles of N19 (d) and N20.1 (h) treated with or without IFN-γ.
TDO-2, tryptophan 2,3-dioxygenase; K/T ratio, kynurenine and tryptophan ratio as a measure of IDO-1/TDO-2 activity; KYNA, kynurenic acid; PIC,
picolinic acid; QUIN, quinolinic acid. Values are expressed as mean ± SE. ***P < 0.001, **P < 0.01 and *P < 0.05. Student's t-test.
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(N19: untreated: −10.345 nM, IFN-γ- treated: −9.234 nM;
N20.1: untreated: −13.345 nM, IFN-γ-treated: −16.356
nM) indicate post-culture concentrations were lower than
that in pre-culture conditions. This suggests exogenous
PIC, present in serum supplemented media, is taken up
and/or catabolized by the oligodendrocytes. Low QUIN
concentrations were also observed in the culture media of
both cell types (Figure 1d and h). Along with the ele-
vated activity of QPRT seen (see Additional file 1) this
suggests an increased uptake and degradation of QUINby oligodendroglial cells. To address this possibility we
next investigated QUIN uptake by N19 and N20.1 cells.Evidence of exogenous QUIN uptake in oligodendrocytes
Using immunocytochemistry, we have demonstrated the
capability of both oligodendrocyte cell lines to take up
exogenous QUIN (Figure 2). This indicates QUIN is ca-
tabolized intracellularly in a time-dependent manner as
fluorescence intensity was directly proportional to the
uptake of QUIN.
N19
0 min 30 min 60 min 90 min
N20.1
Figure 2 Quinolinic acid (QUIN) time-course study. N19 (top row) and N20.1 cells (bottom row) treated with specified concentration of QUIN
for 0, 30, 60 and 90 minutes. Treated cells were analyzed by immunohistochemistry for QUIN uptake.
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QUIN uptake on oligodendroglial cells. A standard curve,
using commercial exogenous QUIN (Sigma-Aldrich, St
Louis, MO, USA), was produced to assess the level of glio-
toxicity by QUIN on N19 and N20.1 cells. This demon-
strated a relatively similar level of tolerance in the two cell
lines to QUIN (Figure 3a and b). There was a notable
trend indicating dose-dependent QUIN toxicity on oligo-
dendrocytes where the LD50 for N19 is 0.5 μM and for
N20.1 is 1 μM for 72 hours. These LD50 values were
chosen as the reference criteria for subsequent QUIN an-
tagonism studies.
Antagonism of QUIN toxicity with neutralizing anti-QUIN
monoclonal antibody (mAb)
Based on the 3 conditions illustrated in Figure 3C and
the presence of LD50 concentrations of QUIN for
72 hours (determined in Figure 3a and b), linear regres-
sion analysis showed that QUIN toxicity on N19 and
N20.1 cell cultures was neutralized by QUIN mAb treat-
ments (Figure 3d and e). We found that treatment with
anti-QUIN mAb diluted at 1/50 (14 ng/μL) led to
complete protection against QUIN excitotoxicity. The
pre-treatment with anti-QUIN mAb group was the least
effective of the assessed treatments. Comparing the
QUIN-PRE treatment groups between both cell lines,
the effect of QUIN-induced cell death at LD50 in N20.1
was more reversible than N19. A validation study was
performed to determine the concentration of anti-QUIN
mAb used in the study was not toxic to the cells (data
not shown).
In addition, we also demonstrated that this strategy
worked on endogenous QUIN present in supernatants
of IFN-γ-treated BV2 microglial cells containing 0.99 ±
0.1 μM of QUIN (data not shown). The glioprotection
observed with the QUIN mAb treatment was found to
be statistically different (P < 0.001) in all the treatment
groups when compared to control cells for both the celltypes (Figure 4). Among the treatment groups for both
cell lines, anti-QUIN mAb at 1/100 (7 ng/μL) or higher
concentration showed full protective effect from QUIN-
induced cell death.
Inhibition of immune-induced QUIN toxicity with IDO
inhibitors
We tested 4 IDO-1 inhibitors including the natural com-
pound berberine and 1-methyl-tryptophan (1MT) iso-
forms D, L and DL for their ability to block IDO-1 and
so stop QUIN production by BV2 cells. We found that
all four inhibitors were able to decrease QUIN induced
toxicity in a dose dependent manner (Figure 5). Prior to
study, IDO-1 inhibitors were tested for toxicity concen-
trations on BV2 cells and were well tolerated above
4 μM (data not shown). At 1 μM, the 4 IDO-1 inhibitors
were able to bring the level of cytotoxicity under the
LD50. At 4 μM, all the IDO-1 inhibitors were able to
completely abolish the QUIN-induced cell death in both
cell lines. Comparing the percentage of cell death be-
tween the 2 cell lines, again we observed that N20.1 cells
were slightly more sensitive to QUIN toxicity. A concen-
tration of 0.5 μM was needed to rescue N19 cells to
LD50 whereas twice as much inhibitor was required to ob-
serve a similar effect in N20.1 cells (P < 0.001). Berberine
was the less effective compound in protecting N19 cells
whilst DL-1MT was the most effective in protecting the
N20.1 cells during QUIN excitotoxicity.
Discussion
The KP profile has been extensively characterized in
various human cell types including neurons, astrocytes,
microglia, endothelial cells and several other immune
cells [14-17]. However, the literature regarding the KP in
oligodendrocytes is very limited [5]. More importantly
the biological function of the KP in oligodendrocytes re-
mains to be delineated. In this study, we showed that
murine oligodendrocytic cell lines express all the KP
µ µ
Figure 3 Neutralization of exogenous quinolinic acid (QUIN) with an anti-QUIN monoclonal antibody (mAb). The QUIN toxicity assay was
investigated in (a) N19 and (b) N20.1 cells treated with various concentration of QUIN (0, 0.05, 0.1, 0.2, 0.5, 1, 2 and 4 μM) for 24 hours, 48 hours
and 72 hours. Lactate dehydrogenase (LDH) activity in culture supernatant was determined. The results were analyzed using linear regression
analysis. (c) The schematic diagram showed the treatment conditions of QUIN and QUIN mAb on oligodendroglial cells. The effect of QUIN mAb
on QUIN toxicity was examined in (d) N19 and (e) N20.1 cells. The levels of LDH released by oligodendroglial cell lines after 72 hours of
incubation with 0.5 μM (N19) and 1 μM (N20.1) of QUIN and varying concentrations of QUIN mAb (30 minutes). The study was performed in
triplicate and the error bars indicate SE. ***P < 0.001.
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trocytes, which lack the mid-stream enzyme KMO that
converts kynurenine to 3-hydroxykynurenine [15]. How-
ever, these data conflict with our previous findings show-
ing that human primary oligodendrocytes lack expressionof both IDO-1 and TDO-2 [5]. These discrepancies are
likely explained by the fact that KP expression: 1) varies
between different species of the same cell type [29-31]
and; 2) is significantly different between primary cells and
their respective cell lines [5]. It is also possible that the
Figure 4 Neutralization of endogenous quinolinic acid (QUIN) with an anti-QUIN monoclonal antibody (mAb). (a) The schematic diagram
represents the effect of QUIN mAb on IFN-γ-treated BV2 supernatant in N19 and N20.1 oligodendroglial cell lines. (b) represents the levels of
lactate dehydrogenase (LDH) released by oligodendroglial cell lines N19 and N20.1, respectively after 72 hours incubation with IFN-γ-treated BV2
and varying concentrations of QUIN mAb. The study was performed in triplicate and the error bars indicate SE. ***P < 0.001.
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simian virus 40 T antigens may alter the KP expression
[17]. Furthermore, in this study we showed that KP me-
tabolism is different between two cell lines of the same
cell type arising from the same species. N20.1 cells dis-
play a more active KP mRNA enzyme expression when
compared to N19 (Figure 1). The degree of gene up-
regulation by IFN-γ was also different: most of the KP
enzymes were induced by IFN-γ in N20.1 cells but only
limited to TDO-2, KAT-2 and KYNU in N19 cells. The
increase of K/T ratio as a result of TDO-2 up-regulation
in these 2 mice oligodendrocytic cell lines was also re-
ported by our group in the human oligodendrocytic
cell line, MO3.13 [5]. It was also demonstrated in a re-
cent study that TDO-2 is highly up-regulated in immor-
talized glial cell lines [32].Figure 5 Effect of IDO inhibition on immune induced QUIN toxicity. T
L-1MT and DL-1MT (0 to 4 μM) on IFN-γ-treated BV2 supernatant in N19 (a
dehydrogenase (LDH) released by oligodendroglial cell lines after 72 hours
performed in triplicate and the error bars indicate SE. ***P < 0.001.The expression of KATs and secretion of KYNA by
both cell lines suggests that the oligodendrocytes are
likely to have neuroprotective functions, especially
during neuroinflammatory events. This is reflected by
higher expression of KAT-II in the presence of IFN-γ
(see Additional file 1). This concurs with current litera-
ture pertaining to the mice model where KAT-2 is dem-
onstrated to be the main enzyme associated with KYNA
production in the brain [33]. Expression of QPRT corre-
sponding with catabolic rather than anabolic activity of
QUIN further supports the neuroprotective role of oli-
godendrocytes. In addition, this suggests that oligoden-
drocytes are capable of taking up exogenous QUIN
present in the extracellular matrix. They could, there-
fore, be involved in the detoxification of pathophysio-
logical concentrations of exogenous QUIN, secreted byhe schematic bar diagram represents the effect of berberine, D-1MT,
) and N20.1 (b) oligodendroglial cell lines. The levels of lactate
incubation with IFN-γ-treated BV2 supernatant. The study was
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further showed a rapid uptake of QUIN by oligodendro-
cytes occurring within 30 minutes then gradually increas-
ing with time (Figure 2). These results are in agreement
with the KP metabolic profile found in human primary oli-
godendrocytes showing an uptake of exogenous QUIN
from media and production of neuroprotective KYNA and
PIC [5]. We previously showed that QUIN is cytotoxic to
both primary human neurons and astrocytes at concentra-
tions as low as 150 nM and 350 nM respectively [10].
As described above, N20.1 cells display a more active
KP compared to N19 cells. This suggests that N20.1 cells
are likely to have a higher tolerance to QUIN toxicity,
that is a higher capacity to catabolize QUIN. Indeed, this
was reflected by the LD50 concentration to QUIN tox-
icity in N20.1 cells with a difference 1-fold higher com-
pared to N19 (Figure 3A). Surprisingly, this was not
reflected in the PRE-QUIN treatment group where cells
are pre-exposed to QUIN followed by treatment with
anti-QUIN mAb (Figure 3D and E). We expected N20.1
cells to have a higher capacity to catabolize QUIN. How-
ever, the cell death assay revealed otherwise. It is import-
ant to note that the QUIN concentrations based on
LD50 used in both cell lines are different. It may imply
that QUIN at approximately 1 μM concentration range
may exert a more permanent and lasting excitotoxic ef-
fect. This is regardless of the cells capacity to take up
and catabolize QUIN. An important aspect to further
dissect is the short-term and long-term effects of QUIN
toxicity on oligodendrocytes. This may have important
implications for neurodegeneration and repair in situa-
tions where the KP is activated for sustained and pro-
longed periods of time, such as progressive MS. We
have previously shown that low micro molar concentra-
tions of QUIN could exert excitotoxicity chronically in
human neurons over a period of 5 weeks [34]. Here, our
data support that from a previous study by Cammer
et al. [8] showing acute QUIN toxicity in primary rat oli-
godendrocytes at micro molar concentrations.
It is interesting to speculate that differences in suscep-
tibility to QUIN-mediated toxicity observed between the
two cell lines may also reflect their different maturation
states and the associated expression of NMDA receptors.
The relatively immature N19 cells, with a lower expression
of NMDA receptors, experience reduced excitotoxicity in
response to QUIN. Furthermore, it is also possible that
there are differences in expression of QUIN transporter
molecules and, therefore, varying levels of QUIN uptake
possible between cell lines. The characterization of NMDA
receptors and the capacity of the QUIN uptake trans-
porter certainly warrant further investigation in oligo-
dendrocyte development.
It is apparent that therapeutic strategies targeting QUIN
could prevent excitotoxicity and ultimately significantlyattenuate neurodegeneration. In this study, we demon-
strated that neutralizing QUIN toxicity using an anti-
QUIN mAb could prevent oligodendrocyte cell death
in vitro. There is still a limited number of studies targeting
QUIN toxicity with a neutralizing antibody, despite exten-
sive evidence showing QUIN as a key excitotoxin involved
in several neuropathological diseases. This study is the
first to propose the use of a mAb to neutralize in vitro
QUIN toxicity. Based on our findings, the application of
neutralizing QUIN with antibodies could be further devel-
oped into monoclonal antibody therapy for neurodegener-
ative diseases such as MS or amyotrophic lateral sclerosis
[35]. Monoclonal antibody therapy has gained popularity
over the years including the recently FDA approved natali-
zumab used in MS treatment [36,37].
As described above, chronic inflammatory responses
can easily trigger cumulative production of pathophysio-
logical concentrations of QUIN by activated monocytic
cells such as infiltrating macrophages and microglia.
This likely creates an environment in which neuronal
cells are highly susceptible to excitotoxicity. Thus, we in-
vestigated further how manipulation of the KP during
inflammation could affect the survival of oligodendro-
cytes towards QUIN-induced toxicity. We attempted to
limit the production of QUIN from the BV2 microglial
cell line by inhibiting IDO-1, since this enzyme is highly
inducible by IFN-γ and will be of pathophysiological
relevance during inflammation. Our data show that the
use of IDO-1 inhibitors (1-MT and berberine) were able
to significantly decrease QUIN production by BV-2 cells
and subsequently lead to complete abolishment of oligo-
dendrocyte cell death at a concentration of 4 μM (Figure 5).
These results represent another relevant therapeutic strat-
egy for MS using KP inhibitors. An earlier study using Ro
61-8048, a KMO inhibitor, on EAE rats showed a signifi-
cant alleviation of disease progression [21]. In this same
study the authors demonstrated that the advantage of
KMO inhibition, in comparison with IDO-1, is that they
could obtain both a decrease of QUIN synthesis and an in-
creased production of the neuroprotective KYNA in the
brain and spinal cord [21].
The use of IDO-1 inhibitors as a treatment for EAE
and MS requires further investigation. The positive out-
comes of this study are based on IDO-1 inhibition spe-
cifically in activated microglial cells. However, there is
no IDO-1 inhibitor able to selectively target cell types.
For example, inhibiting IDO-1 in astrocytes, the main
producers of KYNA [15] would likely be deleterious.
Furthermore, some studies have demonstrated that sys-
temic inhibition of IDO-1 in EAE exacerbates the dis-
ease [38,39]. It is likely that the timing of intervention is
important in this context: normal KP activation certainly
suppresses aberrant immune responses and inhibiting
this effect is unwanted in autoimmune disease. However,
Sundaram et al. Journal of Neuroinflammation  (2014) 11:204 Page 10 of 11excessive KP activation produces neurotoxic metabolites,
so preventing this dysregulated activation of the KP is
clearly neuroprotective. Some KP metabolites have
critical roles in the regulation of the T-cell activity
responsible for autoimmune disorders [39-41]. This fur-
ther supports the notion that the homeostatic activation
of IDO-1 in EAE does have beneficial outcomes. How-
ever, its continued inhibition could also have significant
negative effects in progressive disease.
It is technically challenging to deliver IDO-1 inhibitors
specifically to activated monocytic cells. However, cell-
specific targeting might be possible using nanoparticles
[42]. Another possibility will be to deliver multiple tar-
gets of KP modulators that can limit QUIN production
whilst increasing KYNA and PIC. Platten et al. [43]
demonstrated that tranilast (Rizaben), a synthetic analog
of the KP intermediate 3-HAA, was able to fully abolish
EAE by skewing the immunological profile from pro-
inflammatory to immunosuppressive [43]. Combination
therapy targeting KP enzymes and/or metabolites ap-
pears to be a promising therapeutic for EAE and MS but
requires further investigation.
Conclusions
In conclusion, our data show that the oligodendrocytes
express the major components of KP and, importantly,
are capable of catabolizing exogenous QUIN. Therefore,
they are likely to play a role in the detoxification of exces-
sive QUIN associated with a chronic immune-activated
KP in monocytic cells. More importantly, QUIN is toxic
to oligodendrocytes at pathophysiological concentrations.
Herein, we demonstrated two potential therapeutic strat-
egies to overcome the toxicity of QUIN by directly neu-
tralizing with anti-QUIN mAb and indirectly with KP
inhibitors to limit QUIN production. This work presents
novel therapeutic insights into excitotoxicity and neuro-
protection for oligodendrocytes and other brain cell types.
Main points
 First characterization of the kynurenine pathway
(KP) in oligodendrocytes
 Oligodendrocytes take up QUIN
 QUIN is toxic for oligodendrocytes
 Exogenous QUIN toxicity can be neutralized by
using a monoclonal antibody against QUIN and
specific KP inhibitors leading to increased
oligodendrocyte survival
Additional files
Additional file 1: Expression of kynurenine pathway genes in
oligodendroglial cells. Levels of transcripts in (a) N19 and (b) N20.1
oligodendroglial cell line in differentiated state, with or without IFN-γtreatment. Dots represent mean value from four different experiments.
The levels of transcripts from the genes encoding are IDO1 (indoleamine
2,3-dioxygenase), TDO2 (tryptophan 2,3-dioxygenase), KAT1 (kynurenine
aminotransferase1), KAT2 (kynurenine aminotransferase2), KYNU
(kynureninase), ACMSD (aminocarboxymuconate semialdehyde
decarboxylase) and QPRT (quinolinate phosphoribosyl transferase).
Horizontal line indicates median values. ***P< 0.001, **P < 0.01 and *P< 0.05.
Additional file 2: Expression of kynurenine pathway protein in
oligodendroglial cells. Characterization of the kynurenine pathway in (a)
N19 and (b) N20.1 cells by immunohistochemistry. Cells showed positive
cytoplasmic staining of TDO2 (N19 and N20.1) and KMO (N20.1 only)
after 24 hours IFN-γ treatment. IDO1, QUIN and PIC were absent in this
cells. Nuclei stained with DAPI marker. Scale bar 20 μm. RAW 264.7
cells were used as control for positive-staining of IDO1, TDO2, KMO,
QUIN and PIC.
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